Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

      Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.)

      News provided by

      Astellas Pharma Inc.

      Oct 06, 2026, 19:30 ET

      Share this article

      Share this article


      –  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –

      – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions –

      TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that 21 abstracts from its oncology portfolio will be presented at the European Society for Medical Oncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid, Spain. The presentations span prostate, urothelial, gastric/gastroesophageal junction (GEJ), lung and pancreatic cancers, reflecting Astellas' commitment to advancing standards of care and pursuing new scientific approaches designed for cancers where significant unmet need remains.

      Moitreyee Chatterjee-Kishore, Ph.D., MBA, Executive Vice President and Head of Oncology Development, Astellas:
      "Standards of care do not change by accident. The data being presented at ESMO 2026 demonstrate how a deep understanding of disease biology and differentiated modalities is helping advance care for patients with bladder, gastric, and prostate cancers, including through approaches such as PADCEV™ (enfortumab vedotin) plus pembrolizumab, VYLOY™ (zolbetuximab), and XTANDI™ (enzalutamide). We are building upon this knowledge to develop the next generation of therapeutic options for cancers where unmet needs remain and look forward to engaging in discussions about this work at the congress."

      Highlights from Astellas' ESMO 2026 presentations include:

      • Enfortumab vedotin plus pembrolizumab presentations include the longest follow-up reported to date in locally advanced or metastatic urothelial cancer, along with analyses across patient subgroups and treatment settings. Additional presentations include trials in progress exploring bladder preservation in muscle-invasive bladder cancer.
      • Zolbetuximab presentations examine CLDN18.2 assessment, patient identification and real-world use, reinforcing the growing body of evidence supporting CLDN18.2-guided treatment decisions in gastric and GEJ cancers.
      • Pipeline presentations feature trials-in-progress across Astellas' investigational programs, including Phase 3 trials of setidegrasib in KRAS G12D-mutated pancreatic and non-small cell lung cancers, a Phase 1 trial of ASP5834 in KRAS-mutated or amplified solid tumors, and a Phase 1b/2 trial of ASP546C in CLDN18.2-expressing solid tumors. Together, these investigational studies illustrate Astellas' continued investment in advancing new approaches aimed at overcoming challenges that have limited progress in hard-to-treat cancers.

      Additional details on Astellas' presentations at ESMO 2026 are included below.

      Presentation Title

      Lead Author

      Presentation Details

      Enfortumab vedotin



      EV-103 DE/Cohort A and Cohort K Final
      Analysis:
       Enfortumab vedotin with or
      without pembrolizumab as first-line
      treatment for cisplatin (cis)-ineligible locally
      advanced or metastatic urothelial
      carcinoma: long-term follow-up analysis
      from EV-103 cohorts DE/A and K

      J. P. Maroto Rey

      Type: Rapid oral
      Abstract number: 4740RO
      Date/time: Saturday, October 24,
      10:15-11:45

      EV-302 Comorbidities (DCO3): 
      Enfortumab vedotin plus pembrolizumab for
      previously untreated locally advanced or
      metastatic urothelial carcinoma: updated
      exploratory analysis of EV-302 in older
      patients and those with comorbidities

      S. S. Sridhar

      Type: Poster
      Abstract number: 4761P
      Date/time: Friday, October 23,
      15:15-16:00

      EV-302 Clinical Subgroups (DCO3): 
      Enfortumab vedotin + pembrolizumab in
      previously untreated locally advanced or
      metastatic urothelial cancer: exploratory
      analyses based on disease-related
      characteristics from EV-302

      J. Bedke

      Type: Poster
      Abstract number: 4760P
      Date/time: Friday, October 23,
      15:15-16:00

      EVOLVE 3: Real-world treatment patterns
      in patients with locally advanced and
      metastatic urothelial cancer in France

      F. Joly

      Type: ePoster

      EV-303/KN-905 ITT3: Perioperative
      pembrolizumab or enfortumab vedotin plus
      pembro in participants with muscle-invasive
      bladder cancer who are cisplatin-ineligible:
      ad hoc analysis from KEYNOTE-905

      A. Ullén

      Type: Proffered paper session
      Abstract number: 4733O
      Date/time: Friday, October 23,
      13:30-15:00

      EV-304/KN-B15 ctDNA: ctDNA analysis of
      the phase 3 KEYNOTE-B15 trial:
      neoadjuvant and adjuvant enfortumab
      vedotin + pembrolizumab for participants
      with muscle-invasive bladder cancer who
      are eligible for cisplatin

      J. Chatzkel

      Type: Proffered paper session
      Abstract number: 4734O
      Date/time: Friday, October 23,
      13:30-15:00

      EV-304/KN-B15 ePRO: Health-related
      quality of life with neoadjuvant and adjuvant
      enfortumab vedotin plus pembrolizumab in
      participants (pts) with muscle-invasive
      bladder cancer eligible for cisplatin in the
      phase 3 KEYNOTE-B15 study

      A. Gómez De Liaño

      Type: Rapid oral
      Abstract number: 4738RO
      Date/time: Saturday, October 24,
      10:15-11:45

      EV-209 TiP: EV-209: an open-label, single-arm,
      phase 2 study of enfortumab vedotin plus
      pembrolizumab for bladder preservation in
      patients with muscle-invasive bladder cancer
      eligible for radical cystectomy

      Thomas Powles

      Type: Poster
      Abstract number: 4769TiP
      Date/time: Friday, October 23,
      15:15-16:00

      EV-309 TiP: EV-309: an open-label,
      randomized, phase 3 study of enfortumab
      vedotin plus pembrolizumab for bladder
      preservation in patients with muscle-invasive
      bladder cancer

      Matthew D. Galsky

      Type: Poster
      Abstract number: 4770TiP
      Date/time: Friday, October 23,
      15:15-16:00

      Enzalutamide



      Adelpi REALIZE: High-risk biochemically
      recurrent (hrBCR) hormone sensitive
      prostate cancer (PC): European real-world
      (RW) evidence on risk stratification, PSMA
      PET use, and physician practices

      A. Merseburger

      Type: ePoster
      Abstract number: 2063eP
      Date/time: N/A

      AMNOG NMA in mHSPC: Network meta-analysis
      (NMA) on the safety of androgen receptor pathway
      inhibitors (ARPIs) in patients with metastatic
      hormone-sensitive prostate cancer (mHSPC) from
      German AMNOG dossiers

      C. Ohlmann

      Type: Poster
      Abstract number: 2295P
      Date/time: Friday, October 23,
      15:15-16:00

      CASPER: Outcomes of enzalutamide
      (ENZ) and apalutamide (APA) in metastatic
      hormone-sensitive prostate cancer
      (mHSPC): a Canadian real-world (RW) study

      B. Shayegan

      Type: ePoster
      Abstract number: 2329eP
      Date/time: N/A

      ARCHES/ARANOTE indirect safety
      comparison
      : Indirect safety comparison of
      enzalutamide (ENZA) and darolutamide
      (DARO) with androgen-deprivation therapy
      (ADT) in metastatic hormone-sensitive
      prostate cancer (mHSPC)

      S. Shariat

      Type: Poster
      Abstract number: 2294P
      Date/time: Friday, October 23,
      15:15-16:00

      EMBARK deep PSA response: Deep
      prostate-specific antigen (PSA) response
      by prior definitive treatment (tx) in patients
      (pts) with high-risk biochemically recurrent
      prostate cancer (hrBCR): EMBARK post
      hoc analysis

      S. Freedland

      Type: Poster
      Abstract number: 2293P
      Date/time: Friday, October 23,
      15:15-16:00

      Zolbetuximab



      SPOTLIGHT ctDNA: ctDNA Assessment in
      Patients with CLDN18.2+, HER2−, Locally
      Advanced Unresectable or Metastatic (la/m)
      Gastric or Gastroesophageal Junction
      Adenocarcinoma (G/GEJ a) in SPOTLIGHT

      K. Shitara

      Type: Poster
      Abstract number: 2882P
      Date/time: Sunday, October 25,
      12:00-12:45

      Canadian PSP: Real-World Use of
      Zolbetuximab Plus Chemotherapy (CTx) in
      Patients With CLDN18.2+, HER2−, Locally
      Advanced (LA) Unresectable or Metastatic
      Gastric or Gastroesophageal Junction
      Cancer (mGC/GEJC)  in a Canadian
      Patient Support Program (PSP)

      H. Karachiwala

      Type: Poster
      Abstract number: 2941P
      Date/time: Sunday, October 25,
      12:00-12:45

      Pipeline



      Phase 3 PDAC TiP: A Phase 3, double-blind,
      randomized trial of setidegrasib + mFOLFIRINOX
      or NALIRIFOX as first-line treatment for patients
      with metastatic pancreatic ductal adenocarcinoma
      (PDAC) harboring KRAS G12D mutations: Trial in
      progress

      T. Macarulla

      Type: Poster
      Abstract number: 3190TiP
      Date/time: Sunday, October 25,
      12:00-12:45

      Phase 3 NSCLC TiP: Phase 3,
      randomized, open-label trial of setidegrasib
      vs docetaxel in patients with KRAS G12D-mutated
      locally advanced or metastatic non-small cell lung
      cancer (NSCLC) that progressed on or after
      platinum-based chemotherapy and checkpoint inhibitor
      (CPI) therapy: Trial in progress

      F. Skoulidis

      Type: ePoster
      Abstract number: 2871eTiP
      Date/time: N/A

      Phase 1b/2 TiP: Phase 1b/2 study of
      ASP546C, a Claudin 18.2-targeting
      antibody-drug conjugate with a
      topoisomerase 1 inhibitor payload, in
      patients with Claudin 18.2-expressing
      unresectable locally advanced or metastatic
      solid tumors

      T. Macarulla

      Type: ePoster
      Abstract number: 1133eTiP
      Date/time: N/A

      FiH TiP: A phase 1 study of ASP5834 in
      patients with locally advanced or metastatic
      solid tumors with Kirsten rat sarcoma viral
      oncogene homologue (KRAS) mutations or
      amplifications

      S. Sen

      Type: ePoster
      Abstract number: 1145eTiP
      Date/time: N/A

      Combination clinical data for mss CRC:
      A phase 1/2 study of ASP1570 for locally
      advanced/metastatic microsatellite-stable
      (MSS) colorectal cancer (CRC)

      V. Boni

      Type: ePoster
      Abstract number: 1090eP
      Date/time:
      N/A

      About Astellas
      Astellas is a global life sciences company committed to turning innovative science into value for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

      About PADCEV and the Pfizer, Astellas and MSD Collaboration
      Seagen and Astellas previously entered a clinical collaboration agreement with MSD to evaluate the combination of Seagen's and Astellas' PADCEVTM (enfortumab vedotin) and MSD's KEYTRUDA® (pembrolizumab) in patients with urothelial cancer. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).

      About XTANDI and the Pfizer/Astellas Collaboration
      In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE:PFE), and Astellas (TSE: 4503) entered into a commercial agreement to jointly develop and commercialize XTANDI® (enzalutamide) in the United States, while Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing the product outside the United States. Pfizer receives alliance revenues as a share of U.S. profits and receives royalties on sales outside the U.S.

      Cautionary Notes
      In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions, and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

      SOURCE Astellas Pharma Inc.

      Modal title

      Also from this source

      Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

      Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

      Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") today announced that they have ...

      New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes

      New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes

      Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") presented a new preliminary analysis from the Phase 4 OPTION-VMS...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.